LEO Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, LEO Pharma sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
LEO Pharma: 65 sponsored US clinical trials, 3 recruiting.
LEO Pharma sponsors 65 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 59 completed. 23 of these trials are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 4 trials.
Top-decile sponsor footprint
LEO Pharma ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
59 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
65 total, page 1 of 2
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
NCT05295732
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
NCT05332366
Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
NCT05194540
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
NCT05099133
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
NCT04922021
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
NCT04154293
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
NCT03958955
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
NCT03826901
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
NCT03725722
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
NCT03683719
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
NCT03556592
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
NCT03562377
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
NCT03526861
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
NCT03587805
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
NCT03363854
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
NCT03193372
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
NCT03115476
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
NCT03160885
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
NCT03131648
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
NCT02899962
Biological Effects of LEO 43204 in Actinic Keratosis
NCT02600598
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
NCT02575950
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
NCT02387853
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel
NCT02650505
LEO 124249 Ointment in the Treatment of Alopecia Areata
NCT02561585
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
NCT02549339
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
NCT02547233
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
NCT02547363
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
NCT02424305
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
NCT02361216
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
NCT02305888
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
NCT02602470
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
NCT02100813
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
NCT02120456
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
NCT02124239
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
NCT02038569
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
NCT01998984
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
NCT01922050
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
NCT01982552
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
NCT01866163
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
NCT01820260
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
NCT01555463
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
NCT01536886
LEO 90100 in the Treatment of Psoriasis Vulgaris
NCT01536938
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
NCT01541553
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 24 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the LEO Pharma pipeline
3 recruiting of 65 indexed (5% open); 59 completed (91%).
Phase mix: 23 late (III/IV) vs 38 early (I/II) (early-phase heavy).
Top condition: Atopic Dermatitis (4 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
LEO Pharma: open-pipeline peers nationwide
Peers matched on 65 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
LEO Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 trials (± recruiting share)
- BeiGene · 65 trials · 14% recruiting
- Glaxo Wellcome · 65 trials · 0% recruiting
- Neurocrine Biosciences · 65 trials · 18% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Johnson & Johnson Surgical Vision · 5% recruiting · 22 trials
- Theranica · 5% recruiting · 22 trials
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
Related
What to do with this LEO Pharma page
65 registered trials is a research-attention snapshot, not an endorsement of LEO Pharma or any single study.
- 3 of LEO Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atopic Dermatitis is the condition LEO Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
LEO Pharma pipeline card: 65 registered trials from official public datasets.Report a data error.